Cargando…

Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology

Executive function is an umbrella term that includes cognitive processes such as decision-making, impulse control, attention, behavioral flexibility, and working memory. Each of these processes depends largely upon monoaminergic (dopaminergic, serotonergic, and noradrenergic) neurotransmission in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozga, Jenny E., Povroznik, Jessica M., Engler-Chiurazzi, Elizabeth B., Haar, Cole Vonder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams and Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155367/
https://www.ncbi.nlm.nih.gov/pubmed/30215621
http://dx.doi.org/10.1097/FBP.0000000000000430
_version_ 1783357886614732800
author Ozga, Jenny E.
Povroznik, Jessica M.
Engler-Chiurazzi, Elizabeth B.
Haar, Cole Vonder
author_facet Ozga, Jenny E.
Povroznik, Jessica M.
Engler-Chiurazzi, Elizabeth B.
Haar, Cole Vonder
author_sort Ozga, Jenny E.
collection PubMed
description Executive function is an umbrella term that includes cognitive processes such as decision-making, impulse control, attention, behavioral flexibility, and working memory. Each of these processes depends largely upon monoaminergic (dopaminergic, serotonergic, and noradrenergic) neurotransmission in the frontal cortex, striatum, and hippocampus, among other brain areas. Traumatic brain injury (TBI) induces disruptions in monoaminergic signaling along several steps in the neurotransmission process – synthesis, distribution, and breakdown – and in turn, produces long-lasting deficits in several executive function domains. Understanding how TBI alters monoamingeric neurotransmission and executive function will advance basic knowledge of the underlying principles that govern executive function and potentially further treatment of cognitive deficits following such injury. In this review, we examine the influence of TBI on the following measures of executive function – impulsivity, behavioral flexibility, and working memory. We also describe monoaminergic-systems changes following TBI. Given that TBI patients experience alterations in monoaminergic signaling following injury, they may represent a unique population with regard to pharmacotherapy. We conclude this review by discussing some considerations for pharmacotherapy in the field of TBI.
format Online
Article
Text
id pubmed-6155367
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams and Wilkins
record_format MEDLINE/PubMed
spelling pubmed-61553672018-10-12 Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology Ozga, Jenny E. Povroznik, Jessica M. Engler-Chiurazzi, Elizabeth B. Haar, Cole Vonder Behav Pharmacol Review Articles Executive function is an umbrella term that includes cognitive processes such as decision-making, impulse control, attention, behavioral flexibility, and working memory. Each of these processes depends largely upon monoaminergic (dopaminergic, serotonergic, and noradrenergic) neurotransmission in the frontal cortex, striatum, and hippocampus, among other brain areas. Traumatic brain injury (TBI) induces disruptions in monoaminergic signaling along several steps in the neurotransmission process – synthesis, distribution, and breakdown – and in turn, produces long-lasting deficits in several executive function domains. Understanding how TBI alters monoamingeric neurotransmission and executive function will advance basic knowledge of the underlying principles that govern executive function and potentially further treatment of cognitive deficits following such injury. In this review, we examine the influence of TBI on the following measures of executive function – impulsivity, behavioral flexibility, and working memory. We also describe monoaminergic-systems changes following TBI. Given that TBI patients experience alterations in monoaminergic signaling following injury, they may represent a unique population with regard to pharmacotherapy. We conclude this review by discussing some considerations for pharmacotherapy in the field of TBI. Lippincott Williams and Wilkins 2018-10 2018-09-14 /pmc/articles/PMC6155367/ /pubmed/30215621 http://dx.doi.org/10.1097/FBP.0000000000000430 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Review Articles
Ozga, Jenny E.
Povroznik, Jessica M.
Engler-Chiurazzi, Elizabeth B.
Haar, Cole Vonder
Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
title Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
title_full Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
title_fullStr Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
title_full_unstemmed Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
title_short Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
title_sort executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155367/
https://www.ncbi.nlm.nih.gov/pubmed/30215621
http://dx.doi.org/10.1097/FBP.0000000000000430
work_keys_str_mv AT ozgajennye executivedysfunctionaftertraumaticbraininjuryspecialconsiderationsforbehavioralpharmacology
AT povroznikjessicam executivedysfunctionaftertraumaticbraininjuryspecialconsiderationsforbehavioralpharmacology
AT englerchiurazzielizabethb executivedysfunctionaftertraumaticbraininjuryspecialconsiderationsforbehavioralpharmacology
AT haarcolevonder executivedysfunctionaftertraumaticbraininjuryspecialconsiderationsforbehavioralpharmacology